PHÂN TÍCH CHI PHÍ TRỰC TIẾP Y TẾ CỦA NGƯỜI BỆNH ĐÁI THÁO ĐƯỜNG TÍP 2 DỰA TRÊN DỮ LIỆU THANH TOÁN BẢO HIỂM Y TẾ TẠI CÁC CƠ SỞ KHÁM CHỮA BỆNH TẠI HÀ NỘI GIAI ĐOẠN 2018-2022

Abstract

Background: The rapid increase in chronic diseases such as type 2 diabetes mellitus (T2DM) poses significant challenges not only in terms of healthcare but also in economic aspects for patients and society, especially in major urban centers such as Hanoi. Objective: To analyze the direct medical costs (DMCs) of patients with T2DM based on health insurance (HI) reimbursement data from healthcare facilities in Hanoi during the period 2018–2022. Methods: A cross-sectional descriptive study based on retrospective HI reimbursement data from healthcare facilities in Hanoi during 2018–2022. Results: A total of 1,397,287 patients were included over five years, with a male-to-female ratio ranging from 1:1.07 to 1:1.08, average age ranged from 64.59 ± 11.16 to 64.95 ± 11.78 years, the mean annual direct medical cost per patient ranged from 3,582,051 VND (95% CI: 3,556,188–3,607,914 VND) to 6,951,742 VND (95% CI: 6,895,746–7,007,738 VND), with the majority covered by HI (88.28%–91.88%). Among cost components, medications accounted for the highest proportion (over 50%), followed by laboratory testing (12.69%–17.45%). Conclusion: Compared with the average GDP per capita in 2024 (114 million VND), the mean annual treatment cost per patient with T2DM in Hanoi during 2018–2022 accounted for 0.03%–0.61%, with the majority derived from medication costs and HI coverage. Direct medical costs for T2DM treatment showed an increasing trend annually, with a gradual rise in the proportion borne by patients. Therefore, future health policy interventions should be carefully considered to mitigate the economic burden of the disease, particularly on patients.